Yes, I like the region specific. When they listed companies in the CC I believe, they listed a couple countries of origin. I assume that would be the region. They said “leronlimab for HIV indications” as well, but I assume the company might get leronlimab for the entire region, which complicates negotiations. So the PCa test first would help give enough cash to determine the cancer implications now, allowing a clearer picture with leronlimab later.